WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will
present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA,
April 21-27.
The poster is titled: “Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy”, which can be viewed here: Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy.
The purpose of this study was to assess the accuracy of the sleep monitoring technology in the Quell® device by
comparison to gold standard polysomnography. The study was conducted in collaboration with Dr. John Winkelman of the Massachusetts
General Hospital, Boston, MA.
"Most people with chronic pain have deficient sleep. Quell monitors the user’s sleep to provide objective feedback on this
important outcome and to automatically adjust stimulation to optimize comfort and pain relief. This study evaluated the accuracy of
the monitoring technology in patients with sleep disorders,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix.
“We are pleased with the results and have identified several opportunities for improvement.”
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night
while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell
users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain
sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which
provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through
select
retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
